Immunotherapy in Cervical Cancer: What’s New?

Activity Overview

Nationally recognized experts Dr. Krishnansu S. Tewari and Dr. Bradley J. Monk present the latest clinical trial data and offer privileged insights on the integration of immunotherapy into the treatment armamentarium for advanced cervical cancer.

Credit Expired
0.25 CE Credit(s)
Expires: November 28, 2022

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Integrate current clinical trial data on immune checkpoint inhibitors into treatment plans for patients with cervical cancer.

Activity Faculty


Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA


Bradley J. Monk, MD, FACS, FACOG

Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director, US Oncology Research Network − Gynecologic Program
Vice President and Member Board of Directors, GOG-Foundation
Co-director, GOG-Partners
Phoenix, AZ


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources